Asan Medical Center

Running trials

• Not yet recruiting

  PREventive Invasive Strategy for Obstructive Coronary Artery Disease With Vulnerable Plaque Evaluated by CoroNary Computed Tomography Angiography-2

  NCT07569692· Source

• Not yet recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

  NCT07900633· Phase 3· Source

• Not yet recruiting

  Safety and Efficacy of Autologous Natural Killer Cell Therapy (CHANK-101) in Patients With Recurrent Glioblastoma

  NCT07831161· Source

• Not yet recruiting

  A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment

  NCT07926321· Phase 2· Source

• Not yet recruiting

  Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke

  NCT07730840· Phase 3· Source

• Not yet recruiting

  Predicting Endocrine Resistance Using Molecular Imaging and Liquid Biopsy in Metastatic Breast Cancer

  NCT07867925· Source

• Recruiting

  GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)

  NCT07871435· Phase 1/2· Source

• Recruiting

  Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers

  NCT07566091· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

  NCT07541170· Phase 3· Source

• Recruiting

  Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

  NCT07817875· Phase 3· Source

• Recruiting

  A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

  NCT07701941· Phase 1/2· Source

• Recruiting

  Safety and Efficacy of NDTx-03 in Children and Adolescents With ASD or SCD

  NCT07770867· Source

• Recruiting

  A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

  NCT07811193· Phase 2· Source

• Recruiting

  A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

  NCT07665450· Phase 3· Source

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Source

• Recruiting

  A Phase 1 Study of ATORM-C in Patients With Crohn's Disease

  NCT07822087· Phase 1· Source

• Recruiting

  SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors

  NCT07812805· Phase 1· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

  NCT07775300· Phase 3· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

  NCT07759245· Phase 2· Source

• Not yet recruiting

  Functional And STructural Assesment of the Heart by Artificial Intelligence-enabled Electrocardiogram for the Management of Atrial Fibrillation

  NCT07486739· Source

• Recruiting

  A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

  NCT07492680· Phase 2· Source

• Recruiting

  Treatment Patterns and Survival Outcomes in High-Grade Osteosarcoma: A Multicenter Retrospective Study

  NCT07878364· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Source

• Not yet recruiting

  Evaluation of an Electric Stimulator for Medical Use by Personal (LRTPM1) for Visual Function in Early to Intermediate Dry Age-Related Macular Degeneration

  NCT07700147· Source

• Recruiting

  A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

  NCT07516951· Phase 2· Source

• Not yet recruiting

  Long Term Cohort Study of Adding Ovarian Function Suppression to Tamoxifen in Young Women

  NCT07735897· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

  NCT07581002· Phase 2/3· Source

• Recruiting

  Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration

  NCT07367282· Phase 4· Source

• Recruiting

  Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

  NCT07555938· Phase 3· Source

• Recruiting

  A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

  NCT07668388· Phase 2· Source

• Recruiting

  A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

  NCT07554339· Phase 3· Source

• Recruiting

  Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

  NCT07563881· Phase 3· Source

• Recruiting

  Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

  NCT07486817· Phase 2· Source

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Source

• Recruiting

  A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  NCT07101328· Phase 1· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Source

• Recruiting

  A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

  NCT07525206· Phase 3· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Source

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Source

• Recruiting

  A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

  NCT07393282· Phase 3· Source

• Recruiting

  Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

  NCT07527858· Phase 2· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Source

• Recruiting

  A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

  NCT07549412· Phase 3· Source

• Recruiting

  Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

  NCT07318597· Phase 2· Source

• Recruiting

  A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

  NCT07513376· Phase 3· Source

• Not yet recruiting

  Efficacy and Safety of a Theta Burst Stimulation Protocol of Repetitive Transcranial Magnetic Stimulation in Treatment-Resistant Depression

  NCT07529574· Source

• Recruiting

  LEXURE for Post-Stroke Aphasia

  NCT07570264· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Source

• Active, not recruiting

  AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

  NCT07533175· Phase 3· Source

• Recruiting

  A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

  NCT07489495· Phase 3· Source

Showing 50 of 625.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer56 recruiting
• Colorectal cancer30 recruiting
• Gastric and oesophageal cancer30 recruiting
• Coronary artery disease26 recruiting
• Ovarian cancer25 recruiting
• Liver and biliary tract cancer22 recruiting
• Prostate cancer20 recruiting
• Pancreatic cancer18 recruiting
• Childhood cancers16 recruiting
• Metastatic breast cancer15 recruiting
• Endometrial cancer14 recruiting
• Bladder cancer12 recruiting
• Multiple myeloma12 recruiting
• Head and neck cancer11 recruiting
• Kidney cancer11 recruiting
• Triple-negative breast cancer11 recruiting
• Stroke10 recruiting
• Cervical cancer9 recruiting
• Crohn's disease8 recruiting
• Sarcoma8 recruiting
• Alzheimer disease7 recruiting
• Heart failure7 recruiting
• Obesity7 recruiting
• Diffuse large B-cell lymphoma6 recruiting
• High blood pressure6 recruiting
• Melanoma5 recruiting
• Pulmonary arterial hypertension5 recruiting
• Type 2 diabetes5 recruiting
• Ulcerative colitis5 recruiting
• Acute lymphoblastic leukaemia4 recruiting
• Acute myeloid leukaemia4 recruiting
• Atrial fibrillation4 recruiting
• Idiopathic pulmonary fibrosis4 recruiting
• Depression3 recruiting
• Fatty liver disease (MASLD/MASH)3 recruiting
• Follicular lymphoma3 recruiting
• Glioblastoma3 recruiting
• Neuroendocrine tumours3 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• COPD2 recruiting
• Lupus (SLE)2 recruiting
• Macular degeneration2 recruiting
• Mantle cell lymphoma2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Tuberculosis2 recruiting
• Amyloidosis1 recruiting
• Asthma1 recruiting
• Autism1 recruiting
• Chronic kidney disease1 recruiting
• Epilepsy1 recruiting
• Hepatitis B1 recruiting
• Mesothelioma1 recruiting
• Myasthenia gravis1 recruiting
• Myelodysplastic syndromes1 recruiting
• Parkinson disease1 recruiting
• Polycystic kidney disease1 recruiting
• Primary biliary cholangitis1 recruiting
• Rheumatoid arthritis1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Thyroid cancer1 recruiting

Researchers

• ELEun-Jae Lee
• HJHyemin Jang
• YCYoo Changhoon

Closed trials

• Completed

  The DECISION-CTO Extended 10 Y Follow-up

  NCT06908499· Source

• Withdrawn

  Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis

  NCT06886009· Source

• Recruiting

  Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region

  NCT07370207· Phase 2· Source

• Recruiting

  Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07214779· Phase 3· Source

• Completed

  A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression

  NCT07053345· Phase 4· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

  NCT06921759· Phase 3· Source

• Completed

  Clinical Validity Verification on Diagnostic Assistance for Presence and Severity of Colorectal Cancer and Polyps Using Artificial Intelligence-based Medical Device Software Endoscopic Imaging Assistance

  NCT07744607· Source

• Terminated

  A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

  NCT06585488· Phase 1· Source

• Completed

  A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)

  NCT06624059· Phase 3· Source

• Completed

  A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

  NCT06664801· Phase 2· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Source

• Completed

  To Evaluate the Efficacy and Safety of 'NDTx-01' in Patients With ASD or SCD

  NCT06446193· Source

• Terminated

  A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients

  NCT06186076· Phase 1/2· Source

• Completed

  Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

  NCT06490328· Phase 3· Source

• Completed

  A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor

  NCT06024408· Phase 1· Source

• Completed

  A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

  NCT06280716· Phase 3· Source

• Completed

  A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis

  NCT06224192· Phase 3· Source

• Completed

  A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

  NCT06326047· Phase 2· Source

• Completed

  A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

  NCT06131398· Phase 1· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

  NCT06196879· Phase 2· Source

• Terminated

  A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer

  NCT06016270· Phase 1/2· Source

• Completed

  Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

  NCT06116890· Phase 2· Source

• Completed

  Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

  NCT05954871· Phase 1· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· Source

• Completed

  A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults

  NCT05989048· Phase 3· Source

• Completed

  Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

  NCT06122961· Source

• Terminated

  Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

  NCT06068868· Phase 1· Source

• Recruiting

  Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  NCT05696626· Phase 3· Source

• Completed

  MRI-based Artificial Intelligence Software (NNS-SOT) for Onset Time Estimation in Lesion With Acute Ischemic Stroke

  NCT06160726· Source

• Recruiting

  A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

  NCT06084936· Phase 3· Source

• Recruiting

  DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

  NCT05882058· Phase 2· Source

• Completed

  A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06049017· Phase 2· Source

• Completed

  A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

  NCT05867121· Phase 1· Source

• Terminated

  GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

  NCT05998447· Phase 2· Source

• Completed

  Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

  NCT05882734· Phase 1/2· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of AST-001 in ASD Children

  NCT06333964· Phase 3· Source

• Completed

  A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

  NCT05952856· Phase 3· Source

• Completed

  A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors

  NCT05858164· Phase 1· Source

• Terminated

  The Study for Evaluate of Safety and Efficacy of Vein of Marshall RF Ablation

  NCT05854238· Source

• Completed

  A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

  NCT05909904· Phase 2· Source

• Completed

  A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

  NCT05975073· Phase 1/2· Source

• Completed

  A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

  NCT05907122· Phase 3· Source

• Completed

  Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration

  NCT05953012· Phase 1· Source

• Completed

  A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

  NCT05852691· Phase 2· Source

• Completed

  Arrhythmia Detection With MEMO Patch Plus in Patients With Acute Heart Failure

  NCT07792772· Source

• Completed

  Effects of Hepatic Fibrosis on Hepatic Steatosis Using the Ultrasound Attenuation Imaging in Chronic Hepatitis B

  NCT05871749· Source

• Completed

  A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

  NCT05805501· Phase 2· Source

• Completed

  A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

  NCT05459129· Phase 1/2· Source

• Completed

  To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF

  NCT05483907· Phase 2· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Source

Showing 50 of 314.

Trial sites

• 4100018 - Asan Medical Center1 trial
• Asan Medical Center711 trials
• Asan Medical Center (AMC)9 trials
• Asan Medical Center (AMC) - Site #1111 trial
• Asan Medical Center, Asian Cacer Center1 trial
• Asan Medical Center_Cardiology1 trial
• Asan Medical Center / Clinical Trial Center1 trial
• Asan Medical Center, Department of Oncology1 trial
• Asan Medical Center-Department of Oncology (Site 0405)1 trial
• Asan Medical Center-Department of Oncology (Site 1103)1 trial
• Asan Medical Center-Department of Oncology (Site 1105)1 trial
• Asan Medical Center-Department of Oncology (Site 1300)1 trial
• Asan Medical Center-Department of Oncology (Site 1703)1 trial
• Asan Medical Center-Department of Oncology (Site 1901)1 trial
• Asan Medical Center-Department of Oncology (Site 2352)1 trial
• Asan Medical Center-Department of Oncology (Site 3103)1 trial
• Asan Medical Center-Department of Oncology (Site 3501)1 trial
• Asan Medical Center-Department of Oncology (Site 3901)2 trials
• Asan Medical Center-Department of Oncology (Site 4901)1 trial
• Asan Medical Center-Department of Oncology (Site 5901)1 trial
• Asan Medical Center-Department of Oncology (Site 7901)1 trial
• Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology (Site 2303)1 trial
• Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology (Site 2304)1 trial
• Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology (Site 3401)1 trial
• Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology (Site 3501)1 trial
• Asan Medical Center, Division of Oncology, Department of Internal Medicine1 trial
• Asan Medical Center_Endocrinology2 trials
• Asan Medical Center /ID# 1256011 trial
• Asan Medical Center /ID# 1429741 trial
• Asan Medical Center /ID# 1586961 trial
• Asan Medical Center /ID# 1591551 trial
• Asan Medical Center /ID# 2042361 trial
• Asan Medical Center /ID# 2142941 trial
• Asan Medical Center /ID# 2190541 trial
• Asan Medical Center /ID# 2212271 trial
• Asan Medical Center /ID# 2222801 trial
• Asan Medical Center /ID# 2257581 trial
• Asan Medical Center /ID# 2284441 trial
• Asan Medical Center /ID# 2302821 trial
• Asan Medical Center /ID# 2318861 trial
• Asan Medical Center /ID# 2342731 trial
• Asan Medical Center /ID# 2389121 trial
• Asan Medical Center /ID# 2402861 trial
• Asan Medical Center /ID# 2424001 trial
• Asan Medical Center /ID# 2424091 trial
• Asan Medical Center /ID# 2452151 trial
• Asan Medical Center /ID# 2513121 trial
• Asan Medical Center /ID# 2522891 trial
• Asan Medical Center /ID# 2530441 trial
• Asan Medical Center /ID# 2539551 trial
• Asan Medical Center /ID# 2540221 trial
• Asan Medical Center /ID# 2578451 trial
• Asan Medical Center /ID# 2592551 trial
• Asan Medical Center /ID# 2600101 trial
• Asan Medical Center /ID# 2632201 trial
• Asan Medical Center /ID# 2663411 trial
• Asan Medical Center /ID# 2667991 trial
• Asan Medical Center /ID# 2687171 trial
• Asan Medical Center /ID# 2694801 trial
• Asan Medical Center /ID# 2708981 trial
• Asan Medical Center /ID# 2721301 trial
• Asan Medical Center /ID# 2744541 trial
• Asan Medical Center /ID# 2756001 trial
• Asan Medical Center /ID# 2769551 trial
• Asan Medical Center /ID# 2773711 trial
• Asan Medical Center /ID# 2776031 trial
• Asan Medical Center /ID# 2793951 trial
• Asan Medical Center /ID# 2827321 trial
• Asan Medical Center: Medical Oncology Department1 trial
• Asan Medical Center - Oncology15 trials
• Asan Medical Center - Oncology Department1 trial
• Asan Medical Center - PPDS18 trials
• Asan Medical Center - Pulmonology1 trial
• ASAN Medical Center (Seoul)1 trial
• Asan Medical Center (Site 0006)1 trial
• Asan Medical Center (Site 0031)1 trial
• Asan Medical Center (Site 0064)1 trial
• Asan Medical Center (Site 0072)1 trial
• Asan Medical Center (Site 0076)1 trial
• Asan Medical Center (Site 0082)1 trial
• Asan Medical Center (Site 0163)1 trial
• Asan Medical Center (Site 0200)1 trial
• Asan Medical Center (Site 0289)1 trial
• Asan Medical Center (Site 0300)1 trial
• Asan Medical Center (Site 0310)1 trial
• Asan Medical Center (Site 0460)1 trial
• Asan Medical Center (Site 0503)1 trial
• Asan Medical Center (Site 0603)1 trial
• Asan Medical Center (Site 0701)1 trial
• Asan Medical Center (Site 0830)1 trial
• Asan Medical Center (Site 1062)1 trial
• Asan Medical Center (Site 1102)1 trial
• Asan Medical Center (Site 1200)1 trial
• Asan Medical Center (Site 1303)2 trials
• Asan Medical Center (Site 1313)1 trial
• Asan Medical Center (Site 1355)1 trial
• Asan Medical Center (Site 1404)1 trial
• Asan Medical Center (Site 1601)1 trial
• Asan Medical Center (Site 1602)1 trial
• Asan Medical Center (Site 1800)1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Liver and biliary tract cancer169 works · 70 trials
• Stroke135 works · 21 trials
• Lung cancer111 works · 190 trials
• Colorectal cancer79 works · 69 trials
• Gastric and oesophageal cancer68 works · 86 trials
• Atrial fibrillation56 works · 13 trials
• Asthma42 works · 4 trials
• Kidney cancer38 works · 33 trials
• Crohn's disease36 works · 16 trials
• Ulcerative colitis34 works · 23 trials
• Pancreatic cancer33 works · 37 trials
• Idiopathic pulmonary fibrosis31 works · 13 trials
• Triple-negative breast cancer26 works · 22 trials
• Metastatic breast cancer19 works · 50 trials
• Endometrial cancer16 works · 29 trials
• Neuroendocrine tumours14 works · 7 trials
• Thyroid cancer14 works · 6 trials
• Hepatitis B13 works · 12 trials
• Diabetic eye disease13 works · 4 trials
• Ankylosing spondylitis13 works · 2 trials
• High blood pressure10 works · 16 trials
• Diffuse large B-cell lymphoma10 works · 17 trials
• Neuromyelitis optica (NMOSD)5 works · 1 trial
• Follicular lymphoma5 works · 9 trials